Search company, investor...

Predict your next investment

Venture Capital
vertical-group.com

Investments

137

Portfolio Exits

26

Funds

1

About The Vertical Group

The Vertical Group is a venture capital firm that is focused on the fields of medical technology and biotechnology. For more than 30 years, the principals of The Vertical Group have been founders, early stage investors, major shareholders, and executives of many of the medical technology industry's companies. The Vertical Group manages private partnerships with a "vertical" range of investments including: early and late venture stage companies; private operating companies involved in buy-out or corporate spin-off transactions; and public companies of all sizes. The Vertical Group is the successor to the venture capital division of F. Eberstadt & Co., and has been an independent firm since 1988.

Headquarters Location

106 Allen Road Suite 207

Basking Ridge, New Jersey, 7920,

United States

908-277-3737

Want to inform investors similar to The Vertical Group about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Expert Collections containing The Vertical Group

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find The Vertical Group in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

382 items

Research containing The Vertical Group

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned The Vertical Group in 1 CB Insights research brief, most recently on Feb 2, 2021.

Latest The Vertical Group News

Luminopia Raises $5.7M in Seed Extension Financing

Nov 14, 2022

Luminopia , a Cambridge, MA-based prescription digital therapeutics company, raised $5.7M in Seed Extension funding. The round was led by ShangBay Capital, with participation from Sony Innovation Fund, The Vertical Group, and SSI Strateg. With the closing of the round, William Dai, Founding Managing Partner of ShangBay Capital, will be joining Luminopia’s Board of Directors. The company intends to us the funds for a staged rollout of its lead product for amblyopia to pediatric ophthalmologists starting this month, before expanding to a broader launch in the second half of 2023. Led by CEO Scott Xiao, Luminopia provides treatments for significant neuro-visual disorders. The company is committed to creating digital therapeutics that are both rigorously evaluated for FDA approval and genuinely engaging for patients. As an Innovation Partner of Boston Children’s Hospital, Luminopia is developing its lead product to improve vision in children with amblyopia, the leading cause of vision loss among children. The therapeutic is a clinically validated digital therapy to improve vision in children with amblyopia (lazy eye), the leading cause of vision loss among children, and was approved by the U.S. Food and Drug Administration (FDA) through the De Novo pathway in October 2021. Upon launch, the therapeutic will be prescribed by eye care professionals and distributed through an online retail pharmacy. FinSMEs

The Vertical Group Investments

137 Investments

The Vertical Group has made 137 investments. Their latest investment was in Luminopia as part of their Series A on June 6, 2023.

CBI Logo

The Vertical Group Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/27/2023

Series A

Luminopia

$16M

No

5

10/19/2022

Seed VC

Luminopia

$5.7M

Yes

2

6/20/2022

Series E

MicroTransponder

$73M

Yes

7

4/19/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

12/22/2021

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/27/2023

10/19/2022

6/20/2022

4/19/2022

12/22/2021

Round

Series A

Seed VC

Series E

Series B

Seed VC

Company

Luminopia

Luminopia

MicroTransponder

Subscribe to see more

Subscribe to see more

Amount

$16M

$5.7M

$73M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

5

2

7

10

10

The Vertical Group Portfolio Exits

26 Portfolio Exits

The Vertical Group has 26 portfolio exits. Their latest portfolio exit was Biorez on August 01, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/1/2022

Acquired

$99M

6

7/11/2022

Acquired

$99M

9

9/15/2020

IPO

$99M

Public

5

4/4/2019

IPO

Subscribe to see more

$99M

Subscribe to see more

10

5/6/2016

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/1/2022

7/11/2022

9/15/2020

4/4/2019

5/6/2016

Exit

Acquired

Acquired

IPO

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

6

9

5

10

10

The Vertical Group Acquisitions

2 Acquisitions

The Vertical Group acquired 2 companies. Their latest acquisition was Wright Medical Group on December 20, 1999.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

12/20/1999

Other Venture Capital

$99M

$26.61M

Acquired

3

12/19/1990

Growth Equity

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

12/20/1999

12/19/1990

Investment Stage

Other Venture Capital

Growth Equity

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

$26.61M

$99M

Note

Acquired

Subscribe to see more

Sources

3

10

The Vertical Group Fund History

1 Fund History

The Vertical Group has 1 fund, including Vertical Fund I.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/31/2005

Vertical Fund I

Multi-Stage Venture Capital

Closed

$381M

1

Closing Date

12/31/2005

Fund

Vertical Fund I

Fund Type

Multi-Stage Venture Capital

Status

Closed

Amount

$381M

Sources

1

The Vertical Group Team

9 Team Members

The Vertical Group has 9 team members, including , .

Name

Work History

Title

Status

Tony M. Chou

Founder

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Tony M. Chou

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Founder

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.